ANS014004, a novel small-molecule type II c-Met inhibitor effectively overcomes clinical-resistance MET mutations and exhibits antitumor activity in preclinical models of MET-amplified non-small cell lung cancer (NSCLC) and gastric cancer

被引：0
|
作者：
Li, Gong
Shi, Hepeng
Zhang, Peilong
Li, Xiangqiu
Lan, Wenli
Li, Linna
Chung, David
Schaab, Kevin
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-C145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C145
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
    Kim, Seulki
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Soyeon
    Kim, Miso
    Alm, Yong-Oon
    Keam, Bhumsuk
    Heo, Dae Seog
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 951 - 962
  • [2] MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
    Ramesh, Shrey
    Cifci, Ahmet
    Javeri, Saahil
    Minne, Rachel L.
    Longhurst, Colin A.
    Nickel, Kwangok P.
    Kimple, Randall J.
    Baschnagel, Andrew M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1379 - 1390
  • [3] KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer
    Suzuki, Shinichiro
    Yonesaka, Kimio
    CANCER SCIENCE, 2022, 113 : 1260 - 1260
  • [4] Profiling of MET-Amplified Non-Small Cell Lung Cancer (NSCLC), Correlation to cMET Protein Expression/MET Exon 14 Skipping
    Arguello, David
    Voss, Andreas
    Gatalica, Zoran
    Bender, Ryan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S170 - S170
  • [5] Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
    Wang, K.
    Du, R.
    Roy, S.
    Vokes, N.
    Elamin, Y. Y.
    Hume, C. Bueno
    Skoulidis, F.
    Gay, C.
    Blumenschein, G.
    Fossella, F.
    Tsao, A.
    Lee, J. J.
    Rinsurongkawong, W.
    Rinsurongkawong, V.
    Gibbons, D.
    Vaporciyan, A.
    Zhang, J.
    Heymach, J.
    Altan, M.
    Le, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1016 - S1016
  • [6] Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in EGFR-mutant and MET-amplified non-small cell lung cancer
    Lee, Youngjoo
    Park, Seog-Yun
    Lee, Geon Kook
    Lim, Hyun-Ju
    Choi, Yu-Ra
    Kim, Jaemin
    Han, Ji-Youn
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (10)
  • [7] Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
    Kawada, Ichiro
    Hasina, Rifat
    Arif, Qudsia
    Mueller, Jeffrey
    Smithberger, Erin
    Husain, Aliya N.
    Vokes, Everett E.
    Salgia, Ravi
    CANCER RESEARCH, 2014, 74 (03) : 884 - 895
  • [8] MET second-site mutations in EGFR-mutant, MET-amplified non-small cell lung cancer after resistance to combinatorial targeted therapy.
    Cheng, Jia-Tao
    Yang, Jinji
    Wu, Yilong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase II trial of the c-Met inhibitor tepotinib in patients with advanced non-small cell lung cancer harboring MET exon 14-skipping mutations
    Felip, Enriqueta
    Veillon, Remi
    Viteri, Santiago
    Scheele, Jurgen
    Bruns, Rolf
    Paik, Paul K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] Profiling c-Met and EGFR kinase inhibitor resistance pathways in non-small lung cancer cells
    Bomgarden, Ryan D.
    Jacobs, Ryan
    Fong, Jason
    Moravec, David
    Botting, Gregory M.
    Blank, Michael
    Viner, Rosa I.
    Rogers, John C.
    Puri, Neelu
    CANCER RESEARCH, 2014, 74 (19)
12345